ReviewIntensive care medicine experimental2019
Manipulation of the microbiome in critical illness-probiotics as a preventive measure against ventilator-associated pneumonia.
Review in Intensive care medicine experimental, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Effect of probiotic colonization on oral hygiene and ventilator-associated pneumonia in ICU patients: a triple-blind randomized controlled trial.BMC infectious diseases · 2026Trial
- The gut microbiota composition is linked to subsequent occurrence of ventilator-associated pneumonia in critically ill patients.Microbiology spectrum · 2023Article
- Probiotics, their prophylactic and therapeutic applications in human health development: A review of the literature.Heliyon · 2022Review
- Probiotics in Critically Ill Patients: An Umbrella Review.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2022Article
- Probiotics in the Intensive Care Unit.Antibiotics (Basel, Switzerland) · 2022Review
- Targeting the gut microbiome in the management of sepsis-associated encephalopathy.Frontiers in neurology · 2022Review
- Sepsis and the Human Microbiome. Just Another Kind of Organ Failure? A Review.Journal of clinical medicine · 2021Review
- Altered Ecology of the Respiratory Tract Microbiome and Nosocomial Pneumonia.Frontiers in microbiology · 2021Article
- Do probiotics help prevent ventilator-associated pneumonia in critically ill patients? A systematic review with meta-analysis.ERJ open research · 2021Review
- Mechanical Ventilation Exacerbates Poly (I:C) Induced Acute Lung Injury: Central Role for Caspase-11 and Gut-Lung Axis.Frontiers in immunology · 2021Article
- The use of fecal microbiota transplant in sepsis.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control Study.Nutrients · 2020Article
- The importance of airway and lung microbiome in the critically ill.Critical care (London, England) · 2020Review
- Viral Infections, the Microbiome, and Probiotics.Frontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
objectiveTo describe the possible modes of action of probiotics and provide a systematic review of the current evidence on the efficacy of probiotics to prevent ventilator-associated pneumonia (VAP) in critically ill patients.
methodsWe conducted an unrestricted search of the English language medical literature. For each individual study, the relative risk of VAP was calculated using the reported primary outcome data.
resultsThe search identified a total of 72 articles. Eight articles enrolling a total of 1229 patients fulfilled the inclusion and exclusion criteria. In four trials, the investigators were blinded for the intervention, and two trials used an intention-to-treat analysis. Loss to follow-up with regard to the primary endpoint ranged from 0 to 14% in the intervention groups and from 0 to 16% in the control groups. The incidence of VAP expressed as the percentage of studied patients was reported in seven trials. The incidence of VAP ranged from 4 to 36% in the intervention groups and from 13 to 50% in the control groups. The relative risk for VAP ranged between 0.30 and 1.41. Three trials showed a significant difference in favor of probiotic therapy between the intervention and the control groups.
conclusionsThe incidence of VAP tended to be lower in patients treated with probiotics in most trials identified by the systematic search. Due to the heterogeneity of the studies and the low quality of evidence, it remains difficult to draw firm conclusions. The efficacy of preventive probiotics should be studied in more detail in future trials. Application of probiotics for the prevention of VAP seems to be safe with only few side effects reported in the selected trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.